key: cord-0774368-yg1uhs6u
authors: Yao, Changfu; Bora, Stephanie A; Parimon, Tanyalak; Zaman, Tanzira; Friedman, Oren A; Palatinus, Joseph A; Surapaneni, Nirmala S; Matusov, Yuri P; Chiang, Giuliana Cerro; Kassar, Alexander G; Patel, Nayan; Green, Chelsi ER; Aziz, Adam W; Suri, Harshpreet; Suda, Jo; Lopez, Andres A; Martins, Gislaine A; Stripp, Barry R; Gharib, Sina A; Goodridge, Helen S; Chen, Peter
title: Cell type-specific immune dysregulation in severely ill COVID-19 patients
date: 2020-07-24
journal: medRxiv
DOI: 10.1101/2020.07.23.20161182
sha: cd019197cfacedb65672ee2e17fe63f15d999df6
doc_id: 774368
cord_uid: yg1uhs6u

Coronavirus disease 2019 (COVID-19) has quickly become the most serious pandemic since the 1918 flu pandemic. In extreme situations, patients develop a dysregulated inflammatory lung injury called acute respiratory distress syndrome (ARDS) that causes progressive respiratory failure requiring mechanical ventilatory support. Recent studies have demonstrated immunologic dysfunction in severely ill COVID-19 patients. To further delineate the dysregulated immune response driving more severe clinical course from SARS-CoV-2 infection, we used single-cell RNA sequencing (scRNAseq) to analyze the transcriptome of peripheral blood mononuclear cells (PBMC) from hospitalized COVID-19 patients having mild disease (n = 5), developing ARDS (n = 6), and recovering from ARDS (n = 6). Our data demonstrated an overwhelming inflammatory response with select immunodeficiencies within various immune populations in ARDS patients. Specifically, their monocytes had defects in antigen presentation and deficiencies in interferon responsiveness that contrasted the higher interferon signals in lymphocytes. Furthermore, cytotoxic activity was suppressed in both NK and CD8 lymphocytes whereas B cell activation was deficient, which is consistent with the delayed viral clearance in severely ill COVID-19 patients. Finally, we identified altered signaling pathways in the severe group that suggests immunosenescence and immunometabolic changes could be contributing to the dysfunctional immune response. Our study demonstrates that COVID-19 patients with ARDS have an immunologically distinct response when compared to those with a more innocuous disease course and show a state of immune imbalance in which deficiencies in both the innate and adaptive immune response may be contributing to a more severe disease course in COVID-19.

SARS-CoV-2 infection has quickly spread worldwide to cause the COVID-19 pandemic 1 . Coronaviruses are single, positive-stranded RNA viruses that can infect a range of hosts.

Some are known to cause seasonal, upper respiratory infections (i.e. common colds), but coronaviruses that cause severe lower respiratory infection have emerged, including those that cause severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS), and now COVID-19 2, 3, 4 . SARS-CoV-2 has reached pandemic proportions and is likely to remain a world health emergency for the foreseeable future due to lack of a vaccine, limited treatments, and a high likelihood of recurrent outbreaks. The World Health Organization lists the primary symptoms of COVID-19 as fever, dry cough, and fatigue but also include other symptoms such as diarrhea, loss of taste and smell, and rashes. Those over 60 years of age and people with obesity, cardiovascular disease, and diabetes have the highest risk for severe COVID-19 5, 6 . Most COVID-19 patients have mild respiratory illness, however, about 20% become seriously ill and require hospitalization due to pneumonia 7 . This can progress into acute respiratory distress syndrome (ARDS) and systemic inflammation referred to as "cytokine storm" 8 .

Instead of beneficial antiviral immunity in response to infection, severe COVID-19 is characterized by dysregulated immune responses that allows the virus to persist, causing lung damage, ARDS, and systemic inflammation 9 . While mechanisms underlying SARS-CoV-2 evasion of antiviral immunity and pathogenic inflammation are not clear at this time, commonalities in the pathogenic response with this novel coronavirus and SARS-CoV-1 and MERS-CoV have become apparent 8, 10 . Cells sense RNA viruses using endosomal and cytosolic pattern recognition receptors (PRRs) which signal through other mediators including TNF receptor-associated factors (TRAF) 3 and 6 to activate interferon regulatory factors (IRF) and NFkB, resulting in transcription of early antiviral type I interferons by resident alveolar macrophages (AMs) and epithelial cells in the lungs, which sets up an immune response that clears the virus and resolves inflammation 11 . SARS-CoV-1, and likely SARS-CoV-2, inhibit multiple viral sensing PRRs and downstream signals, effectively blocking recognition of virus and early antiviral type I interferon, and initiating a dysregulated inflammatory cascade that can lead to ARDS and systemic inflammation 12, 13, 14 . Moreover, transcriptomic analysis of PBMC from COVID-19 patients found upregulated pro-inflammatory pathways in monocytes and CD4

T cells, suggesting that the basic hallmarks of the "cytokine storm" in COVID-19 parallel SARS and MERS 15 . However, we are now also appreciating immunologic dysfunctions that may be causing a more severe disease course 16, 17, 18 .

COVID-19 patients have higher circulating levels of IL-6, TNF-a, and CXCL10, particularly those with severe disease, and these "early" cytokines were sustained weeks into infection suggesting an inability to resolve inflammation 19, 20 . Adaptive immune cells recruited from nearby lymph nodes (via circulatory and lymphatic systems) can also contribute to pathogenic inflammation in the lung, particularly if polarized to Th1 and Th17 responses that contribute to neutrophil recruitment and pro-inflammatory monocyte/macrophage activation 21 .

However, severe lung damage due to pneumonia or sepsis is more often characterized by a lack of adaptive immune cells in the periphery 22, 23 . This is due to migration of cells to sites of inflammation, but also T cell dysfunction and death 23, 24, 25 . Prolonged antigen stimulation and pro-inflammatory cytokine exposure cause T cell exhaustion and apoptosis, leading to insufficient B cell activation and loss of the immune resolving functions of T and B cells 26, 27, 28 .

Despite exuberant innate immunity, lymphopenia has been observed in COVID-19 and correlates with poor disease outcome 27, 29 . Characterization of T cells from COVID-19 patients found increased surface expression of exhaustion markers Tim-3 and PD-1, decreased expression of pathways involved in T cell expansion, and increased expression of apoptotic pathways 15, 20, 29 . Therefore, the dysfunction in circulating T and B cells during ARDS may result in an inability to resolve inflammation and perpetuate the systemic inflammation caused by the cytokine storm.

The innate-driven pathogenic inflammation and suppressed adaptive immunity during ARDS in COVID-19 patients indicate dysfunction in immune regulation and the switch from innate to adaptive immunity. To further understand this dysregulated immune response that drives patients to have more severe illness from SARS-CoV-2 infection, we used single-cell RNA sequencing (scRNAseq) to analyze the transcriptome of PBMC collected within the first 5 days of hospitalization of COVID-19 patients with a milder course of disease (mild group) and those that developed ARDS (severe group). Moreover, we investigated the signals that drives lung inflammation in ARDS by comparing the severe group to those recovering from ARDS (recovering group). Having sufficient numbers from each patient group allowed for a deeper analysis of each immune population and evaluation of the functional changes that may determine the severity of illness, as well as delineation of novel pathways that are activated during the resolution of lung inflammation. Severely ill patients had an overall higher activation of inflammatory pathways in comparison to mild and recovering patients. However, we unexpectedly found patients with severe illness secondary to SARS-CoV-2 infection to have monocytes with a blunted interferon response and dysregulation of antigen presentation as well as defective humoral and lymphocyte cytotoxic activity that could be contributing to the delayed viral clearance found in severely ill COVID-19 patients. The implications of these results are that treatment of patients with ARDS from SARS-CoV-2 infection may need a more targeted approach instead of using broad immunosuppression.

We identified and collected blood for buffy coat samples from hospitalized patients confirmed to have SARS-CoV-2 infection (Supplemental Table 1 ). There were no significant differences in age, white blood cell count, cell subsets, and hematocrit between the three groups, but the platelet count was decreased in the severe versus mild group (Fig. 1A & 1B) .

Using available clinical data, we compared the expression of various inflammatory markers in the blood between groups at the time of sample collection and identified a significantly higher level of c-reactive protein in severe patients reflecting the hyperinflammatory state relative to mild patients (Fig. 1C ).

To identify functional differences in the peripheral blood leukocytes that may determine why some patients have milder disease courses whereas others develop ARDS, we used scRNAseq to survey the transcriptome of immune cells in mild, severe, and recovering patients.

A principal component analysis (PCA) of the scRNAseq data from each sample demonstrated clustering by disease severity (Fig. 1D) . The data was then visualized by Uniform Manifold Approximation and Projection (UMAP), and the predominant cellular populations in the peripheral blood were identified using gene expression of canonical markers ( Fig. 1E and Supplemental Fig. 1 ). Clinical counts of lymphocytes and monocytes were used to estimate numbers of NK, CD4 T, CD8 T, B and plasma cells (all considered lymphocytes) and monocytes identified by scRNAseq ( Fig. 1B and 1F ). Consistent with their infrequency among circulating immune cells, insufficient conventional and plasmacytoid dendritic cells (cDCs and pDCs) were captured for analysis. Neutrophils were not identified because they, unlike other peripheral blood subsets, do not tolerate the cell freezing process 16 Cytotoxic lymphocytes have a higher interferon response in severe patients but deficiency in cell killing NK cells are an important arm of the innate lymphocytic antiviral response 30 . We compared the mild versus severe group to identify differences in NK cell function that may determine why some have a more benign course of disease compared to those that develop ARDS (Supplemental Data Fig. 2 ). No significant differences in cell numbers were detected ( Fig. 2A ), yet pathway analysis revealed differences in the NK cell transcriptome between groups. Biological processes that were highly represented by genes upregulated and downregulated in severe patients compared to mild patients were identified ( Fig. 2B and Supplemental Table 2 & 3) . Patients with severe disease have higher viral loads 31 . Accordingly, biological processes such as "response to type I interferon", "response to virus", "response to interferon-gamma", and "response to interferon-beta", among several others characteristic of a higher viral response were significantly upregulated in the severe group compared to mild.

Comparing critically ill patients with ARDS during their acute illness (i.e., severe group) to those that are recovering from severe disease could provide insight into pathways that drive the non-resolving inflammation in ARDS pathogenesis 32 . Thus, we compared the biological processes that were affected by both up-and downregulated genes between severe and recovering groups ( Fig. 2C and Supplemental Table 2 and 3). The recovering group had a resolution of the antiviral pathways, which would be expected from the waning viral load over time. When all three groups were evaluated together, a clear upregulation of the response to both type I and II interferons was found in the severe group in comparison to mild and recovering groups (Fig. 2D) . Despite this response, which reflects higher viral recognition in NK cells in the severe group, genes associated with cytotoxic function were decreased in contrast to the mild and recovering group suggesting a dysfunctional effector antiviral response by NK cells in ARDS patients (Fig. 2E) . Moreover, evaluating the data as individual patients (Supplemental Fig. 2 ) rather than all cells from the patient groups ( Fig. 2D & 2E) revealed the same pattern of changes in interferon signaling and cytotoxic function.

We performed a similar evaluation of CD8 T lymphocytes to investigate the biological processes that differentiate the severity of disease and that are activated during the convalescent phase (Supplemental Fig. 3 ). There was large variability between patients, and no significant differences in cell numbers were detected (Fig. 3A ). CD8 T cells had appropriate activation of interferon signaling that correlated with the disease severity ( Fig. 3B -3D Tables 4 & 5) . We also found a gene signature indicating increased apoptosis in CD8 T cells, which is consistent with prior reports and could be driving the lymphopenia associated with COVID-19 illness (Fig. 3E) 33 . Interestingly, CD8 T cells had a pattern of gene expression that suggested a deficiency in cytotoxic function in both severe and recovering groups in comparison to patients with milder disease (Fig. 3F ). Although this pattern is expected in recovering patients that have resolving SARS-CoV-2 infection, the altered cytotoxic functional pathways in patients with ARDS mirrors the findings of NK cells (Fig.   2E ).

Next, we evaluated CD4 T lymphocytes to determine up-and downregulated biological pathways in mild versus severe and severe versus recovering groups ( Table 6 & 7) . There were no significant differences in CD4 T cell subset numbers between groups (Fig. 4A ), but consistent with NK and CD8 T lymphocytes, the severe group had a higher interferon response in CD4 T cells when compared to mild patients, and this was appropriately diminished in recovering patients ( Fig. 4B-D) . In addition to the antiviral response, several metabolic pathways were elevated in CD4 T cells in severe patients in comparison to other groups, and they also had more activation of apoptotic pathways (Fig. 4B , 4C, 4E, Supplemental Fig. 4E , and Supplemental Table 7 ).

Altogether, these findings indicate that NK and T lymphocytes have an expected response to interferon signaling. Moreover, T lymphocytes are highly metabolic with increased activation of apoptotic pathways. However, both innate and adaptive cytotoxic lymphocytes . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint have dysfunctional cytotoxic activity-associated pathways in severely ill COVID patients who have higher viral titers and delayed clearance of SARS-CoV-2 33 .

B lymphocytes also have an important role in the antiviral response 34 . We identified B cells as well as their subsets to determine the differentially expressed genes between patient groups (Supplemental Fig. 5 ). Numbers of B cell subsets were not consistently different across groups (Fig. 5A ). Similar to NK and T lymphocytes, the B lymphocytes also had higher interferon-mediated responses and activation of apoptotic signals in severe patients compared to both the mild and recovering groups ( . Moreover, B cell activation was upregulated in the recovering group in comparison to severe patients, which is the expected response during the convalescent phase of COVID infection (Fig. 5F ). In contrast, B cells were less activated in the severe group when compared to mild patients indicating a delayed humoral response that could be contributing to the severity of disease (Fig. 5B & 5F ).

In order to understand the pathways that are activated in B cells during the resolution from SARS-CoV-2 infection, we determined the common genes that changed in the comparison of mild versus recovering and severe versus recovering and identified 539 genes that were upregulated in the recovering group in both comparisons (Fig. 5G ). The top canonical pathways enriched among these genes based on the Ingenuity Pathway Analysis (IPA) were in PI3K, IL-3, and IL-4 signaling, which are important signals required for B cell memory and the humoral response (Supplemental Fig. 6 -8 ). We performed a causal network analysis to understand the upstream signals that regulated the differential upregulation of genes in the recovering group and found that SYK, which is a critical signal in B cell differentiation, maturation, and signal transduction by the B cell receptor, was the top upstream regulator candidate among all of the differentially expressed genes (Supplemental Fig. 9 ) 35 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint

Emerging evidence demonstrates disruptions to the myeloid compartment in COVID-19 patients 16 . We evaluated the monocyte subsets and found no differences in cell numbers (Fig.   6A ). As expected, classical monocytes comprised the majority of the cells (Fig. 6B Additionally, in contrast to the lymphocytes, monocytes in severely ill patients had a deficient response to interferon signaling in comparison to mild and recovering groups that could at least partially explain the hypofunctional state that we identified in this cell compartment ( Fig. 6D and Supplemental Fig. 10 ).

To further evaluate the potential mechanisms that were driving the selective immunodeficiencies identified within various cell compartments, we performed a canonical pathway analysis with IPA (Supplemental Tables 12). In contrast to standard GO analysis where activation or inhibition of a process is inferred from up-and downregulation of its member genes respectively, canonical pathway activation incorporates prior knowledge of the overall consequences of up-and down-regulation of individual members of a process in activating or suppressing that pathway (e.g., downregulation of an inhibitor can lead to the activation of a process). In this analysis, we identified CD4 and CD8 T cells as having significant activation of . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 24, 2020. . the T cell exhaustion pathway in the severe versus mild group (Supplemental Table 12 ), which is consistent with other descriptions 16 .

Next, we explored patterns of altered signaling pathway changes across all cell compartments (Fig. 7) . Oxidative phosphorylation pathways were uniformly elevated in the severe group when compared to the mild and recovering groups likely reflecting the increased metabolic state with more severe infection. In contrast, sirtuin signaling pathways were suppressed in severe conditions across all cell compartments. Sirtuins are known mediators of antiviral defense 36, 37 . As with our GO evaluation of biological processes, interferon signaling was decreased in monocytes when comparing severe to mild groups. Similarly, respiratory viral signaling pathways were also uniquely suppressed only within monocytes when comparing severe to mild groups. Notably, PD-1/PD-L1 signaling, an immunologic checkpoint inhibitory pathway, was higher in monocytes within the severe group which could be contributing to the suppressed response of this cellular compartment. Finally, eIF2 signaling was the most significantly downregulated pathway in all cells (except monocytes) when comparing severe to mild groups (Supplemental Fig. 11 ) whereas mTOR signaling was depressed in the severe versus recovering groups.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint

ARDS is driven by a dysregulated inflammatory response that has been largely described as a "cytokine storm" associated with severely ill patients infected with SARS-CoV-2.

A unique feature of the lung injury that perpetuates ARDS is a non-resolving inflammation even after the inciting factor, in this case SARS-CoV-2 infection, has resolved 32 . In the recent months, a growing literature has developed a better understanding of how immune cell dysfunction contributes to the inflammatory response in COVID-19 patients 9 . Several groups have adopted scRNAseq as an approach to functionally interrogate distinct immune compartments 15, 16, 17, 18 . Our data are largely consistent with those findings, but our study further delineates the profound immune dysregulation in COVID-19 patients with severe illness compared to those with milder symptoms and those recovering from ARDS. Because our study obtained a sufficient number of samples within each group at more uniform disease timepoints, we were able to overcome heterogeneity in the data analysis from smaller sample sizes 16 . By selecting patients groups that all had SARS-CoV-2 infection as opposed to comparing to healthy controls, we were also able to deeply interrogate immune cell dysfunction that drives the development of ARDS (i.e., mild versus severe) arising specifically from SARS-CoV-2 infection as well as understanding pathways that are activated during the resolution of inflammation (i.e., severe versus recovering). Using scRNAseq, we evaluated PBMCs and found that although most immune cellular compartments had an expected hyperinflammatory response in severe patients, presumably from the higher viral load and overall higher inflammatory state, several key pathways were dysfunctional in severe patients, which could be contributing to their inability to control the viral infection. Indeed, PBMCs from the severe group had deficiencies in functions necessary to clear virus: cytotoxic killing in NK and T cells, B cell activation, impaired antigen presentation by monocytes. Together, these data suggest functional deficiencies in innate and adaptive immune responses in SARS-CoV-2 infections that could be contributing to the severity of disease.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint

One of the first immunologic features identified in COVID-19 patients was decreased but hyperactive lymphocytes 38, 39 . Our data suggest that both CD4 and CD8 T lymphocytes have a normal response to the viral pathogen with activation of antiviral pathways and a resultant hypermetabolic state. Notably, we found an increase in mitochondrial respiratory chain activity in the severe group, which could reflect a MAVS response to the SARS-CoV-2 infection 40, 41 . It has also been suggested that lymphocytopenia results from increased apoptosis, which is consistent with our findings 20, 42 . Additionally, our analysis indicates that CD8 T lymphocytes have a deficiency in cell killing that could be contributing to the pathobiology of COVID-19. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. Much attention has been devoted to lymphocyte dysfunction in COVID-19, particularly to the importance of cytotoxic T cells in overcoming viral infection 27, 29, 39 . Yet the most dramatic difference we found in the severe group was a marked decline in monocyte function. We identified excessive activation of ER stress in monocytes with a concomitant increase in apoptosis, which could be augmenting death of this cellular compartment in the severe group.

Peripheral blood monocytes also had a deficiency in their response to interferon signaling.

Specifically, type I interferon activity is important during an appropriate antiviral immune response 51 . However, a recent study demonstrated that severe COVID-19 patients have an apparent deficiency in type I interferon signaling 17 . Our findings are congruous with this finding but also further reveal that the deficient type I interferon response emanates from the monocytic compartment in contrast to lymphocytes, which had an appropriate response. Monocytes in circulation from the severe group may be exhibiting immunoparalysis, as our results suggest they were not responsive to interferon signaling 9 . Sudden loss of monocytes and their MHC expression is an indicator of severe acute illness in other conditions characterized by "cytokine storm" such as sepsis and community acquired infections 52, 53 . We also found monocytes to have decreased expression of class I and II MHC genes in the severe group consistent with other descriptions 9, 16 , which may be related to reduced responsiveness to both type I IFN and IFN-g. A concomitant augmentation of PD-1/PD-L1 signaling was found in monocytes, which could lead to the select immunosuppression in this immune population. Additionally, we postulate that suppressed protein translation by an augmented unfolded protein response in monocytes may be further contributing to the immunoparalysis phenotype identified in the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . an inherent defect in their ability to respond to interferon signaling, and this dysfunction may not be ameliorated by simply giving type I interferons to patients at high risk for developing ARDS from SARS-CoV-2 infection 51 . IL-6 is another prominent cytokine that is elevated in the serum of COVID-19 patients and has been tied to the pathogenesis of lung injury. As such, IL-6 blockade (e.g., tocilizumab) has been used in the treatment of COVID-19 patients, and retrospective studies support this as a promising treatment in more severely ill COVID-19 patients 56, 57 . Interestingly, IL-6 suppresses MHC class II expression on monocytes 9, 58 , and treatments such as tocilizumab may not be uniformly immunosuppressive and could be improving the monocyte dysfunction identified by our analysis.

PBMCs. However, immune cells do not express ACE2, the receptor required for viral entry, suggesting an inability for viral infection 59, 60, 61, 62 . Moreover, we did not find any evidence of ACE2 expression or any viral RNA in our scRNAseq of PBMCs (unpublished). The alternative explanation is that genetic, environmental, and age-related changes could confer a predisposition to a dysregulated response to pro-inflammatory signals. This concept has been . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. In summary, our study supports the concept that COVID-19, and especially severe cases that have progressed to ARDS, is characterized by multifaceted immune dysregulation that is not uniformly hyperinflammatory but more accurately described as a state of immune imbalance. Although immune cells have augmented inflammatory signatures in severe patients compared to the mild and recovering groups, they also have distinct patterns of immunoparalysis such as impaired cytotoxic cell killing, attenuated B cell activation, and dysregulated monocyte antigen presentation that could contribute to the severity of illness.

Future research in immune therapies should consider a nuanced approach, particularly those involving targeted augmentation of pathways within specific immune compartments to limit the disease severity as well as promote resolution of the unrelenting inflammation in ARDS.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. Immune cell counts: Lymphocyte and monocyte differential counts from clinical tests were used to estimate cell counts for each immune cell subset. Cells identified as NK cells, CD4 T cells, CD8 T cells, B and plasma cells, proliferating lymphocytes and undefined lymphocytes were collectively considered "total lymphocytes". Lymphocyte subset counts were estimated as:

subset cell count ÷ total lymphocyte count × lymphocyte differential count. Classical and nonclassical monocytes as well as cDCs and pDCs (which have similar morphology for differential counting) were collectively considered "total monocytes". Monocyte subset counts were estimated as: subset cell count ÷ total monocyte count × monocyte differential count. One sample in the recovering patient group lacked differential counts and was therefore excluded from the analysis of immune cell counts.

To understand the biological processes that were enriched by the differentially expressed genes within each immune compartment, we sorted differentially expressed genes (adjusted p value < 0.01) into those that were upregulated or downregulated between two groups (i.e., mild versus severe and severe versus recovering) and did further analysis of gene lists separately. Using Webgestalt (Version 2019) 74 , gene lists were entered to do an over-representation analysis using the gene ontology (GO) database to identify the biological processes that were affected by the differentially expressed genes between severity groups in each cell type.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . that were activated or inhibited between severe vs mild, and severe vs recovering groups in all cell types. FDR<0.01 was used to determine significance of enriched pathways, and z-score was used to determine pathways were activated or inhibited in the severe condition.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint Recovering . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint TCF3  ZBTB7A  VAV3  SUPT6H  CD22  PLCL2  DOCK10  PTPRC  INPP5D  PRKDC  SLC39A10  ITFG2  FCRL3  BCL2  STAT6  TBC1D10C  SYK  IKZF3  POU2F2  AKAP17A  DOCK11  PIK3R1  EP300  LFNG  ITGA4  SWAP70  BTK  FCRL1  ATM  MEF2C  KLF6  BANK1  PRKCB  CD79B  CD180  CD40  LYL1  PTPN6  XBP1  MEF2C  FCRL1  TNFRSF13C  CD81 CD74 CD79A

Severe v. Mild

Severe v. Recovering is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint Supplemental Figure 6 Supplemental Figure 6 . B cell receptor signaling is enriched in the recovering group. IPA canonical pathway analysis of genes significantly upregulated in B cells from recovering vs mild and severe COVID-19 patients. Analysis of the 539 DEGs upregulated (red) only in the recovering group shows increased signaling through the B cell receptor compared to mild and severe groups.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 24, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint Supplemental Figure 9 . Increased B cell receptor signaling is the recovery group is regulated by SYK. IPA causal pathway analysis demonstrates that SYK is the primary upstream mediator of the upregulated pathways in B cells from recovering vs mild and severe groups.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint Supplemental Figure 11 . The eIF2 signaling pathway is differentially expressed in immune cells from COVID-19 patients. Gene product interaction network analysis of the eIF2 pathway, which is down-regulated in lymphocytes, but not not myeloid cells, in the severe vs mild group.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161182 doi: medRxiv preprint

A Novel Coronavirus from Patients with Pneumonia in China

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Origin and evolution of pathogenic coronaviruses

Pre-existing traits associated with covid-19 illness severity

Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

Complex Immune Dysregulation in COVID-19

Patients with Severe Respiratory Failure

COVID-19: Immunology and treatment options

Toll-like receptors in antiviral innate immunity

Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex

SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6

Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

Insights into the immunopathogenesis of acute respiratory distress syndrome

Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality

Susceptibility to programmed cell death in T-lymphocytes from septic patients: a mechanism for lymphopenia and Th2 predominance

Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways

T cell pathways involving CTLA4 contribute to a model of acute lung injury

Acute Viral Respiratory Infection Rapidly Induces a CD8+ T Cell Exhaustion-like Phenotype

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

T cell exhaustion during persistent viral infections

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Natural Killer Cells: Development, Maturation, and Clinical Utilization

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

The acute respiratory distress syndrome

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Antiviral B cell and T cell immunity in the lungs

The SYK tyrosine kinase: a crucial player in diverse biological functions

Sirtuins are evolutionarily conserved viral restriction factors

Intricate Roles of Mammalian Sirtuins in Defense against Viral Pathogens

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Immunological and inflammatory profiles in mild and severe cases of COVID-19

Virus Control of Cell Metabolism for Replication and Evasion of Host Immune Responses

SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome

Immunology of COVID-19: Current State of the Science

Clinical characteristics and factors associated with long-term viral excretion in patients with SARS-CoV-2 infection: a single center 28-day study

Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19

Characterization of T-Dependent and T-Independent B Cell Responses to a Virus-like Particle

Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Identification of high and low responders to lipopolysaccharide in normal subjects: an unbiased approach to identify modulators of innate immunity

Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Front Immunol

NAD+ and sirtuins in aging and disease

Foundations of Immunometabolism and Implications for Metabolic Health and Disease

Metabolism and autophagy in the immune system: immunometabolism comes of age

PBMC fixation and processing for Chromium single-cell RNA sequencing

Comprehensive Integration of Single-Cell Data

SoupX removes ambient RNA contamination from droplet based single cell RNA sequencing data

Fast, sensitive and accurate integration of single-cell data with Harmony

We thank the staff of the Biobank & Translational Research Core, the Flow Cytometry Core, and the Applied Genomics, Computation & Translational Core for their help in this project. This work